Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simula

Showing results (291-300 of 296) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 296 results.
Hematological Oncology|July 1, 2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinibOlga Mulas, Giovanni Caocci, Mario Annunziata, et al.
The European Physical Journal. C, Particles and Fields|October 17, 2017
Review of lattice results concerning low-energy particle physics: Flavour Lattice Averaging Group (FLAG)S Aoki, Y Aoki, D Bečirević, et al.
International Journal of Cardiology|November 13, 2019
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitorsGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Annals of Hematology|January 3, 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinibGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Blood Cancer Journal|June 10, 2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML studyGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Annals of Hematology|June 1, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitorsOlga Mulas, Giovanni Caocci, Fabio Stagno, et al.
Pageof 30

Showing results (291-300 of 296) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 296 results.
Hematological Oncology|July 1, 2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinibOlga Mulas, Giovanni Caocci, Mario Annunziata, et al.
The European Physical Journal. C, Particles and Fields|October 17, 2017
Review of lattice results concerning low-energy particle physics: Flavour Lattice Averaging Group (FLAG)S Aoki, Y Aoki, D Bečirević, et al.
International Journal of Cardiology|November 13, 2019
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitorsGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Annals of Hematology|January 3, 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinibGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Blood Cancer Journal|June 10, 2020
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML studyGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Annals of Hematology|June 1, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitorsOlga Mulas, Giovanni Caocci, Fabio Stagno, et al.
Pageof 30